Why the study?
Recent reports suggested an association between RAAS inhibitor use and SARS-CoV-2 vulnerability, possibly mediated by higher ACE2 concentrations.
Does the use of RAAS inhibitors or male sex affect plasma ACE2 concentrations in patients with heart failure?
Does the use of RAAS inhibitors or male sex affect plasma ACE2 concentrations in patients with heart failure?
In patients with heart failure, male sex is associated with higher plasma ACE2 concentrations, whereas ACE inhibitor or ARB use is not, challenging the hypothesis that these drugs increase COVID-19 vulnerability via ACE2 upregulation.
No takes yet. Share an insight, caveat, or question.
ACE2 higher in men with HF but unaffected by RAAS inhibitors; leaves open any link to SARS-CoV-2 susceptibility.
Sama et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: